Small molecule · developed by ASTRAZENECA
Laroprovstat (AZD0780) is an orally administered daily agent studied in heterozygous familial hypercholesterolaemia and hypercholesterolemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07930507 | Phase 3 | Hypercholesterolemia | Not yet recruiting | AZN |
| NCT06834932 | Phase 2/3 | Dyslipidaemia | Active not recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Heterozygous Familial HypercholesterolaemiaHypercholesterolemia
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →